KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial.

Lori A Devlin, Denise C Babineau, Stephanie L Merhar, Sara B DeMauro, Walter K Kraft, Scott A Lorch, Abhik Das, Scott A McDonald, Evan Rhodes, Augusto F Schmidt, Lillian Trochinski, Margaret Crawford, Thitinart Sithisarn, Lawrence Leeman, Kelley Zagol Kovatis, Namasivayam Ambalavanan, Ryan W Smith, Sucheta Telang, Jennifer A Tioseco, Jennifer M McAllister, Scott L Wexelblatt, Bhanu Muniyappa, Patricia K Williams, Susan C Adeniyi-Jones, Crystal D Hill, Tanner Wright, Gregory M Sokol, Lynette Johnson, Richard W Hall, Scott D Duncan, Karen Puopolo, Krishna Dummula, Ann Anderson-Berry, Jonathan M Davis, Brenda Poindexter, Leslie W Young, HEAL Evaluation of Limited Pharmacotherapies for Neonatal Opioid Withdrawal Syndrome (HELP for NOWS) Consortium

JAMA 335(24) 2114-2125

PMID42033722
PMCIDPMC13110413
DOI10.1001/jama.2026.5782
发表日期2026-04-25
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 flow diagram。
摘要

摘要

IMPORTANCE: Infants with neonatal opioid withdrawal syndrome (NOWS) who receive pharmacologic treatment are traditionally treated with a scheduled opioid taper. An alternate approach, symptom-based dosing, may better align treatment with withdrawal severity. OBJECTIVE: To compare time from birth to medical readiness for discharge for infants with moderate to severe withdrawal treated with either a symptom-based dosing or scheduled opioid taper approach. DESIGN, SETTING, AND PARTICIPANTS: In this cluster, crossover randomized clinical trial with run-in period, 23 US hospitals cared for infants using the Eat, Sleep, Console approach (ESC) or Finnegan-based care (a comprehensive scoring system to quantify severity of symptoms; 15 ESC and 8 Finnegan hospitals) and their preferred primary opioid. Opioid dosing was guided by study-approved, site-specific algorithms. Infants with NOWS with a gestational age at birth of at least 36 weeks and at risk for pharmacologic treatment were enrolled between March 25, 2024, and April 9, 2025, with the last 3-month assessment on July 15, 2025. Sample size analyses were conducted between August 1, 2024, and September 23, 2024. INTERVENTION: Sites were randomized to 1 of 2 sequences: (1) symptom-based dosing followed by scheduled opioid taper or (2) scheduled opioid taper followed by symptom-based dosing. MAIN OUTCOME AND MEASURE: Time from birth to medical readiness for discharge. RESULTS: Of the 626 enrolled infants (mean [SD] gestational age, 38 [1] weeks; 49% male), 383 were cared for with ESC (primary outcome cohort). The mean time to medical readiness for discharge was significantly shorter in the symptom-based dosing group compared with the scheduled opioid taper group (9.18 vs 11.61 days; adjusted mean ratio [aMR], 0.79 [95% CI, 0.65-0.96]). There was no difference in the risk for initiation of pharmacologic treatment (0.4 vs 0.41; adjusted risk ratio, 0.99 [95% CI, 0.77-1.27]) or length of stay (10.91 vs 12.09 days; aMR, 0.9 [95% CI, 0.72-1.13]) between groups. For infants in the symptom-based group, 35% (95% CI, 25%-45%) required scheduled opioid dosing due to withdrawal severity that was not controlled with intermittent dosing. In the Finnegan cohort (n = 243; planned secondary outcome), there were no significant differences in time to medical readiness for discharge (15.99 vs 17.56 days; aMR, 0.91 [95% CI, 0.72-1.15]) or length of stay (17.38 vs 19.39 days; aMR, 0.9 [95% CI, 0.69-1.16]). The inpatient composite safety outcome occurred rarely (in the ESC cohort, 3 of 188 in the symptom-based dosing vs 2 of 195 in the scheduled opioid taper groups). CONCLUSIONS AND RELEVANCE: Symptom-based dosing decreased time to medical readiness for discharge compared with a scheduled opioid taper approach among infants cared for with ESC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05980260.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1:. Trial Intervention Groups This figure details the dosing intervention groups for the OPTimize NOW Trial
非 KM Figure
Figure 2Figure 2:. Recruitment, Randomization, and Follow-up Assessment for the Optimize NOW Trial a Failed inclusion criteria: No antenatal exposure identified (n=4, [ 4 & 0 ]), Did not meet the study definition of at risk for pharmacologic treatment (n=11, [ 6 & 5 ]), and gestational age at birth less than 36 weeks (n=27, [ 19 & 8 ]). b Met Exclusion criteria: Major birth defects (n=8, [ 6 & 2 ]), neonatal encephalopathy (n=2, [ 2 & 0 ]), postnatal opioid exposure prior to NOWS treatment (n=9, [ 3 & 6 ]), Receipt of respiratory support at 48 hours (n=60, [ 42 & 18 ]), Outborn and received pharmacologic treatment at transferring hospital (n=15, [ 2 & 13 ]). Multiple exclusion criteria (n=6, [ 5 & 1 ]). c The critical safety outcome (non-accidental trauma and death) was assessed through media review for all infants. Data for the outpatient safety outcome (Acute/urgent care or emergency room visits and hospital readmissions) was not recorded for 153 infants. These infants were evenly distributed between dosing groups in the ESC cohort [symptom-based dosing 50 (26%) , scheduled opioid taper 49 (25%) ] and Finnegan cohort [ 27 (23% ), scheduled opioid taper 27 (22%) ]. If data were not recorded, the study assumption was that the event did not occur.
非 KM Figure